01—Abstract
Summary
Summary of the 10-Q filed August 6, 2025. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. (COR) reported strong revenue growth in its fiscal third quarter of 2025, with an 8.7% increase year-over-year, reaching $80.7 billiona.
This growth was driven by solid performance across both its U.S. and International Healthcare Solutions segments. Notably, the U.S. segment saw a significant contribution from increased sales of GLP-1 class drugs for diabetes and weight loss, which grew 18.6%b in the quarter. Profitability also showed improvement, with gross profit rising 20.6% year-over-year, largely due to higher sales volumes and the positive impact of a LIFO credit this year compared to an expense last year.
The acquisition of Retina Consultants of America (RCA) in January 2025 has begun to contribute positively to the U.S. segment's results. While operating expenses increased, primarily due to integration costs from RCA, overall segment operating income grew by 20.6%c. The company also continues to manage its debt effectively, with significant credit facility capacity, and reiterated its commitment to shareholder returns through dividends and share repurchases.
02—Key points
Key Highlights
- Revenue increased by 8.7% to $80.7 billion for the third quarter, driven by strong performance in both U.S. and International segments.
- U.S. Healthcare Solutions segment revenue grew 8.5%, significantly boosted by a 18.6% increase in sales of GLP-1 class drugs.
- Gross profit saw a substantial increase of 20.6% year-over-year, aided by higher sales and a favorable LIFO credit.
- The acquisition of Retina Consultants of America (RCA) in January 2025 is contributing to the U.S. segment's revenue and profit growth.
- Operating income increased by 29.0% for the quarter, reflecting improved gross profit and operational efficiencies.
- The company has maintained robust liquidity, with substantial availability under its multi-currency revolving credit facility and receivables securitization facility.
- Cencora continues its share repurchase program, with $882.2 million remaining authorization as of June 30, 2025, and has increased its quarterly dividend.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2025, Cencora, Inc. kept $0.01.
- Revenue$80.66B100.0%
- Cost of revenue−$77.76B96.4%
- Gross profit$2.91B3.6%
- Operating costs−$2.04B2.5%
- Operating income$867.7M1.1%
- Interest, other & tax−$180.3M0.2%
- Net income$687.4M0.9%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed August 6, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $80.66B$74.24B | +8.7% |
| Cost of Revenue | $77.76B$71.83B | +8.2% |
| Gross Profit | $2.91B$2.41B | +20.6% |
| SG&A Expenses | $1.67B$1.38B | +20.9% |
| Operating Income | $867.65M$672.48M | +29.0% |
| Net Income | $687.40M$483.46M | +42.2% |
| EPS (Basic) | $3.55$2.44 | +45.5% |
| EPS (Diluted) | $3.52$2.42 | +45.5% |
| Shares Outstanding (Basic) | 193.82M198.26M | −2.2% |
| Shares Outstanding (Diluted) | 195.23M200.05M | −2.4% |
05—Questions
Frequently Asked Questions
How did Cencora's revenue perform in the third quarter of fiscal year 2025?
Cencora reported a strong revenue performance, with an increase of 8.7% year-over-year to $80.7 billion. This growth was primarily driven by increased sales volumes across both the U.S. Healthcare Solutions and International Healthcare Solutions segments.
What were the key drivers of revenue growth in the U.S. Healthcare Solutions segment?
The U.S. Healthcare Solutions segment saw its revenue increase by 8.5%, largely due to overall market growth driven by unit volume. A significant contributor was the 18.6% increase in sales of products in the GLP-1 class for diabetes and weight loss, alongside increased sales of specialty products to physician practices and health systems. The recent acquisition of RCA also contributed to this segment's growth.
How has the company's profitability been affected by recent events and acquisitions?
Gross profit increased by 20.6% year-over-year, benefiting from higher sales and a LIFO credit in the current period versus an expense in the prior year. The acquisition of RCA in January 2025 is positively impacting the U.S. segment's profitability. While operating expenses rose due to acquisition and integration costs, overall segment operating income increased by 20.6%.
What is the company's current financial position and liquidity outlook?
Cencora maintains a strong liquidity position with significant availability under its credit facilities, including a $4.5 billion multi-currency revolving credit facility and a $1.5 billion receivables securitization facility. The company's operating cash flows are expected to be sufficient to fund its ongoing requirements, including debt repayments, dividends, and capital expenditures.
06—Continue